METASTATIC UVEAL MELANOMA

This study tests a drug called tebentafusp combined with treatments directed at the liver (like embolization or chemo-embolization) for people with a rare eye cancer (uveal melanoma) that has spread to the liver. About 109 adults with a specific immune type (HLA-A*0201) will part…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …

This early-stage trial tests a personalized cell therapy called lifileucel for people with advanced uveal melanoma (a rare eye cancer) or certain sarcomas (connective tissue cancers). The treatment involves removing immune cells from the patient's tumor, growing them in a lab, an…

This study tests whether a new drug called RP2, given with nivolumab, works better than the current standard combination (ipilimumab plus nivolumab) for people with metastatic uveal melanoma, a rare eye cancer that has spread. About 280 adults who have not had prior immunotherapy…

This study tests a two-step treatment for people with a rare eye cancer (uveal melanoma) that has spread only to the liver. First, a chemotherapy drug is delivered directly to the liver through a special procedure. Then, an immunotherapy drug is given to help the immune system at…

This phase 2 trial is testing a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that has spread to the liver. Participants receive weekly infusions for 6 months, then may have surgery to remove any remaining tumors. The goal is to see if the drug can …

This study tests whether combining a targeted immunotherapy (tebentafusp) with a liver-directed radiation treatment (Y-90 radioembolization) can help control metastatic uveal melanoma that has spread to the liver. About 30 adults whose cancer is mainly in the liver and who have a…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This study tests whether two drugs, cemiplimab and ziv-aflibercept, can shrink or stop the growth of metastatic uveal melanoma, a rare eye cancer that has spread. About 32 adults with this condition will receive the combination treatment. The goal is to see if the drugs work bett…

This study tests an experimental drug called NBM-BMX in people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The goal is to find the best dose, check for side effects, and see if the drug can shrink or slow tumors. Participants take…